Not FDA-approved2,3Evidence: Large human trialsHeart and blood vessels

Nesiritide1,3

Also called Natrecor2,3

Key takeaway

Nesiritide is a recombinant form of human B-type natriuretic peptide, a 32-amino-acid peptide, according to FDA’s substance registry. It was the active ingredient in Natrecor, which FDA approved in 2001.1,3 In ASCEND-HF, a randomized trial of 7,141 people hospitalized with acute heart failure, nesiritide did not significantly reduce death or rehospitalization or meet its goal for breathlessness, and it caused more low blood pressure.4 FDA withdrew Natrecor’s approval in 2020 after the company told FDA it was no longer marketed.2

Nesiritide at a glance

What it isRecombinant human B-type (brain) natriuretic peptide of 32 amino acids, also recorded as BNP-32, according to FDA’s substance registry.1
FDA statusNot FDA-approved. FDA withdrew approval of Natrecor, NDA 020920, as of June 15, 2020, after the applicant reported it was no longer marketed.2,3
Human evidenceLarge randomized trials, including ASCEND-HF in 7,141 people with acute heart failure, published in 2011.4
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is nesiritide?

Nesiritide is a recombinant form of human B-type natriuretic peptide of 32 amino acids. FDA’s substance registry also records it as BNP-32 and brain natriuretic peptide 32.1

It was the active ingredient of Natrecor, approved under NDA 020920 on August 10, 2001, according to Drugs@FDA.3

How is nesiritide thought to work?

The sources reviewed here do not describe its mechanism. The ASCEND-HF investigators describe it as approved in the United States for early relief of breathlessness in acute heart failure.1,4

What do human studies show?

ASCEND-HF randomized 7,141 people hospitalized with acute heart failure to nesiritide or placebo on top of standard care. Moderate or marked improvement in breathlessness was slightly more common with nesiritide, but the difference did not reach the trial’s prespecified level of significance.4

Rehospitalization for heart failure or death within 30 days occurred in 9.4% given nesiritide and 10.1% given placebo, a difference that was not significant. Kidney function did not worsen more often, but low blood pressure was more common with nesiritide.4

The investigators concluded that nesiritide could not be recommended for routine use in the broad population of people with acute heart failure.4

What the evidence base contains

  • Large randomized human trial ASCEND-HF (NCT00475852): a randomized, placebo-controlled trial of 7,141 people hospitalized with acute heart failure, published in 2011.4

Evidence-strength label: Large randomized human trials. How this label is assigned

Is nesiritide FDA-approved?

Not now. FDA’s May 14, 2020 Federal Register notice states that approval of 16 applications, including Natrecor, NDA 020920, is withdrawn as of June 15, 2020, because the applicants reported that the products were no longer marketed and asked for withdrawal.2

Drugs@FDA lists Natrecor with an original approval date of August 10, 2001.3

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list nesiritide.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Nesiritide is not among them.6,7

Timeline

  1. FDA approves Natrecor, NDA 020920, according to Drugs@FDA.3
  2. The ASCEND-HF trial of nesiritide in 7,141 people with acute heart failure is published.4
  3. FDA’s withdrawal of Natrecor’s approval takes effect, according to its May 14, 2020 Federal Register notice.2

What is still unknown?

Whether any group of people with acute heart failure benefits clearly: ASCEND-HF found no significant effect on its main outcomes across the broad population it studied.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Nesiritide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Nesiritide are a bounded selection, not every registration or paper about Nesiritide. For the years before Nesiritide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Nesiritide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Nesiritide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA approval withdrawn in 2020 after the product left the market. A randomized trial of 7,141 people with acute heart failure found no significant effect on death or rehospitalization and more low blood pressure. Nesiritide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Nesiritide?

FDA approval withdrawn in 2020 after the product left the market. A randomized trial of 7,141 people with acute heart failure found no significant effect on death or rehospitalization and more low blood pressure. Nesiritide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
18
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Nesiritide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

56Selected dated records
63Connected citations
18Populated source years1998–2026
3/4Record lanes present

Registered human studies

Trial composition

25 of 25 selected trial records include at least one phase value; 25 of 25 include a status value in the retained structured contract.

PhasesPhase 2 12Phase 3 8Phase 1 7Phase 4 3Not applicable 1
Status at observationCompleted 24Recruiting 1

PubMed bibliography

Publication composition

25 of 25 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 24Review 19Comparative Study 5Randomized Controlled Trial 4Research Support, Non-U.S. Gov't 4Case Reports 1Clinical Trial 1Comment 1Editorial 1English Abstract 1Meta-Analysis 1Research Support, N.I.H., Extramural 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
5
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
56

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 56 dated records

Research hub

Explore the Nesiritide evidence record

Open all 56 records →
56Dated records
3Evidence types
56Cited public sources
18Source years

Change ledger

Recently changed for Nesiritide

Open all 56 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00091520

PeptideScanner retained ClinicalTrials.gov record NCT00091520 at 2026-11-16T01:39:41.882Z. Its registry update date was 2011-05-20, and PeptideScanner's reviewed identity mapping was nesiritide.

PeptideScanner change date
November 16, 2026
Cited source date
May 20, 2011
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00119691

PeptideScanner retained ClinicalTrials.gov record NCT00119691 at 2026-11-16T01:39:41.882Z. Its registry update date was 2013-09-12, and PeptideScanner's reviewed identity mapping was nesiritide.

PeptideScanner change date
November 16, 2026
Cited source date
September 12, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00170183

PeptideScanner retained ClinicalTrials.gov record NCT00170183 at 2026-11-16T01:39:41.882Z. Its registry update date was 2009-11-16, and PeptideScanner's reviewed identity mapping was nesiritide.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2009
Evidence lane
Clinical trials

Official-source collections

Source records for Nesiritide

Open the full research atlas →
PubMed25

25 with attributed title, venue, publication-date, and type metadata.

  1. Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis.The Journal of international medical research · 2020 Jan
  2. Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials.Expert review of cardiovascular therapy · 2015 05 31
  3. Levosimendan and nesiritide as a combination therapy in patients with acute heart failure.The American journal of the medical sciences · 2015 May
Explore all selected literature →
ClinicalTrials.gov25

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT01544998Registry update March 22, 2018 · completed at observation
  2. NCT01977859Registry update February 14, 2018 · completed at observation
  3. NCT02608996Registry update January 3, 2018 · current at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span December 23, 1998 to November 8, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2,3,5
  • U.S. Department of Health and Human Services6
Dated updates connected to this profile · 56

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Nesiritide in acute decompensated heart failure: current status and future perspectives.↗

    PubMed lists PMID 18953274 in Reviews in cardiovascular medicine as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2008 Summer (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Nesiritide: the clinical experience.↗

    PubMed lists PMID 18629384 in The Canadian journal of cardiology as Journal Article, Review, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Nesiritide following maze and mitral valve surgery.↗

    PubMed lists PMID 18928481 in Journal of cardiac surgery as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Regulatory

    Federal Register notice 2021-00118↗

    The Federal Register published notice 2021-00118, attributed to FDA and its parent HHS department, on 2021-01-08. Its official title is “Determination That ARALEN (Chloroquine Phosphate) Oral Tablets, 500 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.↗

  5. Literature metadata

    Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis.↗

    PubMed lists PMID 31948318 in The Journal of international medical research as Journal Article, Meta-Analysis, with publication-date metadata of 2020-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Regulatory

    Federal Register notice 2020-10367↗

    The Federal Register published notice 2020-10367, attributed to FDA and its parent HHS department, on 2020-05-14. Its official title is “Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.↗

  7. Literature metadata

    Practical application of nonrandomized research to patient care: a case study of nesiritide.↗

    PubMed lists PMID 17192168 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment.↗

    PubMed lists PMID 17461695 in Pharmacotherapy as Journal Article, Review, with publication-date metadata of 2007-05 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Decompensated heart failure: is there a role for the outpatient use of nesiritide?↗

    PubMed lists PMID 15470300 in Congestive heart failure (Greenwich, Conn.) as Journal Article, Review, with publication-date metadata of 2004 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure.↗

    PubMed lists PMID 15605677 in International journal of clinical practice as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2004-11 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Nesiritide for the treatment of congestive heart failure.↗

    PubMed lists PMID 15102572 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2004-04 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure.↗

    PubMed lists PMID 16509026 in Pharmacotherapy as Comparative Study, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2006-01 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Nesiritide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications (May 14, 2020) · FR Doc. 2020-10367 ↗

    Federal Register · Official source · Source checked November 15, 2026

  3. 3
    Drugs@FDA: NATRECOR (nesiritide), NDA 020920 · original approval August 10, 2001 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  4. 4
    Effect of nesiritide in patients with acute decompensated heart failure (2011) · PMID 21732835 ↗

    The New England Journal of Medicine · Official source · Source checked November 15, 2026

  5. 5
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026